| Zhao, Ming |
NCT02435953: TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma |
|
|
| Recruiting | 4 | 1 | RoW | TACE, RFA | Ming Zhao | Hepatocellular Carcinoma, Chemoembolization, Therapeutic, Ablation Techniques, RFA | 05/23 | | | |
NCT05231382: Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 426 | RoW | Raltitrexed, oxaliplatin (SALOX) treatment, Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment | Sun Yat-sen University | Hepatocellular Carcinoma | 02/24 | 02/25 | | |
NCT05220020: TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer |
|
|
| Recruiting | 3 | 299 | RoW | TACE(Transcatheter arterial chemoembolization), Lenvatinib, Lenvatinib oral | Sun Yat-sen University | Hepatocellular Carcinoma | 02/24 | 02/25 | | |
DurHope, NCT04945720: Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Hepatic artery infusion chemotherapy（HAIC）, Durvalumab, Durvalumab Injection | Sun Yat-sen University | Hepatocellular Carcinoma | 07/23 | 12/23 | | |
NCT04663035: Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC |
|
|
| Recruiting | 2 | 120 | RoW | Tislelizumab, Tislelizumab Injection, Ablation | Ming Zhao | Recurrent Hepatocellular Carcinoma | 12/23 | 12/25 | | |
| Recruiting | 1/2 | 287 | US, RoW | DB-1310 | DualityBio Inc. | Advanced Solid Tumor | 08/26 | 08/26 | | |
NCT05609695: Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 100 | RoW | Immune checkpoint inhibitor | Sun Yat-sen University | Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma | 03/25 | 09/25 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
NCT05573282: Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 50 | RoW | Regorafenib combine with ICIs | Sun Yat-sen University | Hepatocellular Carcinoma | 06/25 | 01/26 | | |
NCT05002452: Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC |
|
|
| Recruiting | N/A | 150 | RoW | Search of factors predicting therapeutic effects and prognosis | Sun Yat-sen University | Hepatocellular Carcinoma | 07/25 | 12/25 | | |
NCT05718492: A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents |
|
|
| Recruiting | N/A | 100 | RoW | digital subtraction angiography., FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil ) | Sun Yat-sen University | Hepatocellular Carcinoma | 10/25 | 10/26 | | |
| Recruiting | N/A | 250 | RoW | inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group. | Second Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, Sun Yat-sen University | Lung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer | 07/30 | 07/39 | | |
